Lung Cancer最新文献

{"title":"Letter: Alectinib combined with cobimetinib in ALK-rearranged lung cancer: A phase IB study","authors":"Fatima Naveed, Saad Khan, Ayesha Khan, Faraz Arshad, Rizwan Ahmad","doi":"10.1016/j.lungcan.2025.108489","DOIUrl":"10.1016/j.lungcan.2025.108489","url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"202 ","pages":"Article 108489"},"PeriodicalIF":4.5,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143674262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Precision projections of the delay of resistance mutations in non-small cell lung cancer via suppression of APOBEC","authors":"Orestis Nousias ,&nbsp;Jeffrey D. Mandell ,&nbsp;Karen S. Anderson ,&nbsp;Jeffrey P. Townsend","doi":"10.1016/j.lungcan.2025.108487","DOIUrl":"10.1016/j.lungcan.2025.108487","url":null,"abstract":"<div><div>Genomic instability driven by stress-response-dependent mutagenesis is a key factor in cancer progression. Tyrosine kinase inhibitor therapy, a common treatment for non-small cell lung cancer, induces mutations that can facilitate the evolution of drug resistance and therapeutic failure. Here we quantified the contribution of APOBEC to mutational signatures in non-small cell lung cancer patients undergoing TKI therapy. By analyzing tumor sequence data to infer gene-specific and patient-specific trinucleotide mutation rates, we projected the potential delay of resistance obtained by suppression of APOBEC mutation. Our data-driven analysis indicates that inhibition of APOBEC activity would substantially extend therapeutic efficacy, with the degree of benefit varying based on patient-specific APOBEC mutagenesis levels. Personalized therapeutic strategies that target APOBEC offer promise for the enhancement of TKI treatment efficacy by delaying the evolution of drug resistance in lung cancer. Development of clinically safe inhibitors for use in combination with tyrosine kinase inhibitors could significantly limit tumor genetic variation and improve outcomes for non-small cell lung cancer patients.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"202 ","pages":"Article 108487"},"PeriodicalIF":4.5,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143628819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world safety and effectiveness of entrectinib in Japanese patients with ROS1 gene fusion-positive, unresectable, advanced/recurrent non-small cell lung cancer: Post-marketing surveillance","authors":"Takashi Seto ,&nbsp;Sayuri Nakane ,&nbsp;Lyu Ji ,&nbsp;Yuya Ueda ,&nbsp;Hiroshi Sugano ,&nbsp;Nobuki Takei ,&nbsp;Mizuki Kobayashi ,&nbsp;Ayako Murayama ,&nbsp;Noboru Yamamoto","doi":"10.1016/j.lungcan.2025.108478","DOIUrl":"10.1016/j.lungcan.2025.108478","url":null,"abstract":"<div><h3>Objectives</h3><div>To evaluate the safety and effectiveness of entrectinib, an orally-administered potent multi-kinase inhibitor, for the treatment of proto-oncogene tyrosine-protein kinase-1 (<em>ROS1</em>) gene fusion-positive, unresectable, advanced/recurrent non-small cell lung cancer (NSCLC) in Japan.</div></div><div><h3>Materials and methods</h3><div>Patients with <em>ROS1</em> gene fusion-positive, unresectable, advanced/recurrent NSCLC who initiated entrectinib therapy were enrolled in this all-case post marketing surveillance between February 21, 2020 and November 30, 2021. Outcomes were to identify the: (1) type and onset of initial cognitive disorder and ataxia during entrectinib therapy; (2) status of treatment and outcome of drug-related cognitive disorder and ataxia events; (3) incidence of other adverse drug reactions (ADRs) of safety concern: cognitive disorder and/or ataxia, cardiac disorder (excluding QT interval prolongation), QT interval prolongation, syncope, and interstitial lung disease; (4) incidence of serious adverse events (AEs) and ADRs; and (5) effectiveness.</div></div><div><h3>Results</h3><div>Of the 276 patients who initiated entrectinib, 269 and 260 were included in the safety and effectiveness analysis sets, respectively. Cognitive disorder/ataxia was the most common ADR of safety concern, occurring in 72 patients (26.8 %). The median time to onset of initial cognitive disorder/ataxia symptoms was 2.0 days. Overall, entrectinib dose reduction, interruption, or discontinuation occurred in 9.7 %, 28.3 %, and 15.2 % of patients, respectively. Most ADRs of safety concern were manageable; 86.9 % of patients with ADRs were recovered/recovering. Serious AEs were reported in 42.8 % of patients. The overall response rate (ORR) was 38.8 % and median time to treatment failure was 6.4 months. ORR was 70.8 % versus 26.8 % to 34.7 % with entrectinib as first-line versus second- or later-line treatment, and 65.3 % versus 28.2 % in patients without versus with a history of tyrosine kinase inhibitor treatment.</div></div><div><h3>Conclusions</h3><div>Consistent with clinical trials, entrectinib is tolerable and effective in Japanese patients with <em>ROS1</em> gene fusion-positive, unresectable, advanced/recurrent NSCLC.</div><div><strong>Study registration:</strong> UMIN Clinical Trials Registry (UMIN000046619).</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"203 ","pages":"Article 108478"},"PeriodicalIF":4.5,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143747373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomic profiling of aggressive pathologic features in lung adenocarcinoma","authors":"Yi-Duo Lin ,&nbsp;Hong-Ji Li ,&nbsp;Hui-Zhao Hong ,&nbsp;Yi-Fan Qi ,&nbsp;Yun-Yi Li ,&nbsp;Xue-Ning Yang ,&nbsp;Yi-Long Wu ,&nbsp;Wen-Zhao Zhong","doi":"10.1016/j.lungcan.2025.108460","DOIUrl":"10.1016/j.lungcan.2025.108460","url":null,"abstract":"<div><h3>Introduction</h3><div>Pathologic features involving LVI (lympho-vascular invasion), PNI (perineural invasion), STAS (spread through air spaces), and Grade 3 pattern (from the International Association for the Study of Lung Cancer grading system) are related to having an aggressive phenotype and linked to poor prognosis. However, few studies have conducted in-depth analyses of these features simultaneously with genomic profiling.</div></div><div><h3>Methods</h3><div>A total of 1559 sequencing of adenocarcinoma samples were included in the common driver mutations analysis, 1306 samples were brought into genomic mapping analysis. OncoSG’s East Asian ancestry dataset was implemented for Tumor-Node-Metastasis-Biomarker (TNMB) classification and prognostic assessment.</div></div><div><h3>Results</h3><div>EGFR was more significantly prevalent in LVI negativity (P = 0.021), STAS negativity (P = 0.002), and moderate grade (P &lt; 0.001). ALK was significantly interrelated with LVI (P = 0.028), STAS (P &lt; 0.001), and poor grade (P &lt; 0.001); ROS1 and STAS positivity (P = 0.031), poor grade (P = 0.016) were significantly related. KRAS (P = 0.003) and BRAF-V600E (P = 0.002) were only significantly intertwined with poor grade. Apart from common driver mutations, TP53, CHEK2, KEAP1, PTEN, RB1, NF1 were significantly enriched in LVI samples (P &lt; 0.05). TP53, PTEN, CTNNB1, HGF, NF1 were more prominent in STAS (P &lt; 0.01). TP53, LRP1B, NF1 were significantly more prevalent in Grade 3 pattern (P &lt; 0.001). The mixture of STK11, PTEN, and TOP2A generated by exclusive mutations may be a potential predictor of TNMB categorization towards survival. The HR of stage II compared I of TNMB was 2.28 (95 % CI 1.36–3.86, P &lt; 0.001), while stage III compared II was 1.95 (95 % CI 1.04–3.21, P = 0.031).</div></div><div><h3>Conclusions</h3><div>This analysis demonstrated the correlation of pathologic features with common driver mutations, key mutations and canonical oncogenic signaling pathways. The data highlighted the similarities and differences among these features horizontally, and provide new insights in TNMB classification and prognostic assessment.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"203 ","pages":"Article 108460"},"PeriodicalIF":4.5,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143747374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implications of EGFR expression on EGFR signaling dependency and adaptive immunity against EGFR-mutated lung adenocarcinoma","authors":"Masahiro Torasawa ,&nbsp;Tatsuya Yoshida ,&nbsp;Kouya Shiraishi ,&nbsp;Shigehiro Yagishita ,&nbsp;Hanako Ono ,&nbsp;Yuji Uehara ,&nbsp;Jun Miyakoshi ,&nbsp;Akiko Tateishi ,&nbsp;Yukiko Shimoda Igawa ,&nbsp;Ryoko Inaba Higashiyama ,&nbsp;Akifumi Mochizuki ,&nbsp;Ken Masuda ,&nbsp;Yuji Matsumoto ,&nbsp;Yuki Shinno ,&nbsp;Yusuke Okuma ,&nbsp;Yasushi Goto ,&nbsp;Hidehito Horinouchi ,&nbsp;Ryuji Hamamoto ,&nbsp;Noboru Yamamoto ,&nbsp;Shun-ichi Watanabe ,&nbsp;Yuichiro Ohe","doi":"10.1016/j.lungcan.2025.108494","DOIUrl":"10.1016/j.lungcan.2025.108494","url":null,"abstract":"<div><h3>Background</h3><div>In EGFR-mutated lung adenocarcinoma (<em>EGFR</em>m LUAD), <em>EGFR</em> mutations do not necessarily result in increased <em>EGFR</em> expression (EGFR-exp), which differs among patients. However, the factors influencing EGFR-exp and the impact of EGFR-exp on tumor characteristics in patients with <em>EGFR</em>m LUAD remain unclear.</div></div><div><h3>Patients and methods</h3><div>Whole-exome and RNA sequencing were performed for patients with early- and advanced-stage <em>EGFR</em>m LUAD. The patients were classified into low or high EGFR-exp groups based on the median transcripts per million. We retrospectively examined the association between EGFR-exp, genomic characteristics, downstream <em>EGFR</em> signaling activity, tumor microenvironment (TME) status, and clinical outcomes.</div></div><div><h3>Results</h3><div>This study included 450 and 45 patients in the early- and advanced-stage cohorts, respectively. In both cohorts, the EGFR-exp low group exhibited a lower incidence of <em>TP53</em> co-mutations and <em>EGFR</em> amplification and a higher incidence of <em>EGFR</em> subclonal mutations than the EGFR-exp high group. Furthermore, downstream <em>EGFR</em> signaling pathways, such as the MAPK signaling, were less activated in the EGFR-exp low group. However, this group showed significantly enriched adaptive immune response pathways (<em>Q</em> &lt; 0.0001) and an immune-inflamed TME. Additionally, a low EGFR-exp was a significantly favorable factor for postoperative relapse (odds ratio [OR], 0.6; <em>P</em> = 0.04). However, in the advanced-stage cohort, a low EGFR-exp was a significant risk factor for non-responders to osimertinib (OR, 17.5; <em>P</em> = 0.03).</div></div><div><h3>Conclusions</h3><div>In EGFRm LUAD, significant associations were observed between EGFR-exp levels and both EGFR signaling pathways and adaptive immune status, which in turn influence clinical outcomes. This large-scale multi-omics analysis highlights the heterogeneity among patients with <em>EGFR</em>m LUAD and emphasizes the need to assess EGFR-exp levels alongside mutation status for optimal treatment strategies in <em>EGFR</em>m LUAD.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"202 ","pages":"Article 108494"},"PeriodicalIF":4.5,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143619675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathological & radiological variables in the diagnosis of bronchopulmonary carcinoids (BPCs) with a focus on Antigen Kiel 67 (Ki-67) proliferation index","authors":"Gaurav Ahuja ,&nbsp;Aparna Iyer ,&nbsp;Rachel Harwood ,&nbsp;Haval Balata ,&nbsp;Christopher Craig ,&nbsp;Philip A.J. Crosbie ,&nbsp;Kath Hewitt ,&nbsp;Karen Peplow ,&nbsp;Deborah Hutchings ,&nbsp;Anna Sharman ,&nbsp;Paul Bishop ,&nbsp;Leena Joseph ,&nbsp;Antonio Paiva-Correia ,&nbsp;Anshuman Chaturvedi ,&nbsp;James Barr ,&nbsp;Angela Leek ,&nbsp;Alison Backen ,&nbsp;Christina Nuttall ,&nbsp;Oliver Kennedy ,&nbsp;Andrew Williamson ,&nbsp;Matthew Evison","doi":"10.1016/j.lungcan.2025.108493","DOIUrl":"10.1016/j.lungcan.2025.108493","url":null,"abstract":"<div><h3>Background</h3><div>Bronchopulmonary carcinoids (BPCs) are classified into typical carcinoids (TC) and atypical carcinoids (AC), based on the mitotic count and absence/presence of necrosis on pathology specimens. There are limitations to accurate measurement of these criteria. It important to study other markers like Ki-67, to enhance the diagnostic accuracy of lung carcinoids.</div></div><div><h3>Objective and methodology</h3><div>Retrospective analysis of BPCs treated with surgery between 2012–2022, to examine the accuracy of Ki-67 on the diagnostic specimen, concordance of diagnostic and resection specimens, diagnostic accuracy of Positron Emission Tomography (PET) and concordance of clinical and pathological staging.</div></div><div><h3>Results</h3><div>205 patients were included in the analysis (final diagnosis TC 180, AC 25). Mean age 60.5 years and 68 % female. Ki-67 (&lt;5% vs. 5–30 %) on diagnostic biopsy, available in 64 % (n = 131) of the cohort, had specificity (diagnose TC correctly) of 89.4 % (95 %CI 80.4 %-94.7 %) and sensitivity (diagnose AC correctly) of 77.8 % (40.2 %-96.1 %). This compared to 97.5 % (90.3 %-99.6 %) and 36.4 % (12.4 %-68.4 %) for mitotic count (&lt;2mitoses/2mm² vs. 2-10mitoses/2mm²) and 100 % (94.4 %-100 %) and 21.4 % (5.7 %-51.2 %) for necrosis (absence vs. presence). A pre-resection diagnosis of TC (including surgical biopsy) shows better concordance with final diagnosis on resection specimen (94.9 %, 95 %CI 88.7 %-97.9 %, n = 117) as compared to the diagnosis of AC 83.3 % (95 %CI 50.9 %-97.1 %, n = 12). Concordance for AC appears higher with image guided lung biopsy 80 % (95 % CI, 29.9 %-98.9 %) than bronchoscopy 50 % (9.5 %-90.5 %). SUVmax on 18FDG-PET was a modest predictor of BPC sub-type with an AUC of 0.684 (95 % CI: 0.545,0.823). The clinical and pathological staging were concordant in 46 % (85/184) cases. However, 27 % (50/184) were upstaged and 13 % (23/172) found to have occult nodal metastases on pathology review of the surgical specimens.</div></div><div><h3>Conclusion</h3><div>The diagnosis and sub-typing of BPCs on diagnostic specimens is challenging. Our data suggest Ki-67 could increase diagnostic accuracy, but further research is needed to confirm this.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"202 ","pages":"Article 108493"},"PeriodicalIF":4.5,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143636794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From data to prediction: Digital chest drain insights into postoperative recovery after lung cancer surgery","authors":"Koen C.H.A. Verkoulen ,&nbsp;Iris E.W.G. Laven ,&nbsp;Jean H.T. Daemen ,&nbsp;Aimée J.P.M. Franssen ,&nbsp;Michiel H.M. Gronenschild ,&nbsp;Karel W.E. Hulsewé ,&nbsp;Yvonne L.J. Vissers ,&nbsp;Alessandro Brunelli ,&nbsp;Kostas Papagiannopoulos ,&nbsp;Erik R. de Loos","doi":"10.1016/j.lungcan.2025.108486","DOIUrl":"10.1016/j.lungcan.2025.108486","url":null,"abstract":"<div><h3>Objective</h3><div>Prolonged air leak is one of the major complications following lung cancer surgery and objectively measured digital drainage data have been investigated as predictive factors. With this scoping review, we aim to provide a comprehensive overview of risk factors, derived from digital drainage data, for predicting postoperative (drainage) course after pulmonary resection in patients with lung cancer.</div></div><div><h3>Methods</h3><div>MEDLINE and EMBASE were systematically searched for studies that investigated digital drainage data after lung cancer surgery. Systematic reviews, editorials, commentaries, and reports in languages other than English were excluded. Data on general study information, characteristics of the procedures, digital drainage parameters, and clinical postoperative outcomes were extracted.</div></div><div><h3>Results</h3><div>Twenty-three studies were included, comprising 3,649 patients. Four different digital drainage systems were used. Maximum air flow exceeding 100–200 ml/min (5 studies), variable air leak patterns (3 studies), and less negative intrapleural/differential pressure (7 studies) were associated with prolonged air leak. A mean air flow of &lt;50 ml/min was associated with spontaneous air leak resolution (1 study). However, chest tube management was heterogeneous, with different suction levels and chest tube removal criteria being applied.</div></div><div><h3>Conclusions</h3><div>Mean and maximum air flow, air leak patterns, and intrapleural/differential pressure derived from digital drainage data can be considered as possible predictors for postoperative prolonged air leak after lung cancer surgery. However, definitive evidence on the use of these predictive factors in a future risk prediction model could not be provided, due to a lack of homogeneity in the chest tube strategies used in the reviewed studies.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"202 ","pages":"Article 108486"},"PeriodicalIF":4.5,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143644047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A phase 1b study of cofetuzumab pelidotin monotherapy in patients with PTK7-expressing recurrent non-small cell lung cancer","authors":"Byoung Chul Cho ,&nbsp;Melissa Johnson ,&nbsp;Jair Bar ,&nbsp;Eric Schaefer ,&nbsp;Kiyotaka Yoh ,&nbsp;Alona Zer ,&nbsp;Mor Moskovitz ,&nbsp;Se-Hoon Lee ,&nbsp;Victor Moreno ,&nbsp;Maria de Miguel ,&nbsp;Yusuke Okuma ,&nbsp;Joo-Hang Kim ,&nbsp;Chun-Hui Lee ,&nbsp;Julio Peguero ,&nbsp;Peter Ansell ,&nbsp;Carla Biesdorf ,&nbsp;Rabih Saab ,&nbsp;Kevin J. Freise ,&nbsp;David Ramies ,&nbsp;Edwin E. Jeng ,&nbsp;D. Ross Camidge","doi":"10.1016/j.lungcan.2025.108492","DOIUrl":"10.1016/j.lungcan.2025.108492","url":null,"abstract":"<div><h3>Background</h3><div>Protein tyrosine kinase 7 (PTK7) overexpression in lung cancer is associated with tumor progression. Cofetuzumab pelidotin (Cofe-P) is an antibody-drug conjugate comprising an anti-PTK7 antibody conjugated to a microtubule inhibitor. Herein, we report the results of a phase 1b study evaluating Cofe-P safety, efficacy, and pharmacokinetics in patients with recurrent non-small cell lung cancer (NSCLC).</div></div><div><h3>Methods</h3><div>This signal-seeking phase 1b, open-label, multicenter, single-arm study enrolled patients with PTK7-expressing recurrent NSCLC. Cofe-P was administered at 2.8 mg/kg intravenously once every 3 weeks. The primary endpoint was objective response rate (ORR) and secondary endpoints were duration of response (DOR), progression-free survival (PFS), and overall survival (OS).</div></div><div><h3>Results</h3><div>Overall, 65 patients received Cofe-P; 51 had PTK7 expression of ≥90 % tumor cells with ≥2+ staining intensity by immunohistochemistry. All patients reported adverse events (AEs), most commonly alopecia (52 %) and decreased neutrophil count (43 %); 69 % had grade ≥3 AEs, including grade ≥3 neutropenia in 25 %. Treatment-related AEs were reported in 94 % of patients; none were fatal. Overall, ORR was 18 %; in patients with PTK7 expression of ≥90 % tumor cells with ≥2+ staining and non-squamous epidermal growth factor receptor (<em>EGFR</em>) wild type or mutant, or squamous NSCLC, ORR was 21 %, 15 %, and 13 %, respectively. Overall, median DOR was 7.2 months, median PFS was 5.5 months, and median OS was 12.6 months; longest DOR (median 9.0 months), PFS (median 6.8 months), and OS (median 12.6 months) were in patients with non-squamous <em>EGFR-</em>mutant NSCLC.</div></div><div><h3>Conclusions</h3><div>Cofe-P demonstrated a manageable safety profile and preliminary efficacy across NSCLC histologies and <em>EGFR</em> mutation status. These data support PTK7 as a valid therapeutic target for NSCLC.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"202 ","pages":"Article 108492"},"PeriodicalIF":4.5,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143611747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"National clinical practice patterns of uniportal video-assisted thoracoscopic anatomical lung resections: nationwide population-based data from a clinical audit registry","authors":"Iris E.W.G. Laven ,&nbsp;Aimée J.P.M. Franssen ,&nbsp;Michiel H.M. Gronenschild ,&nbsp;David J. Heineman ,&nbsp;Wilhelmina H. Schreurs ,&nbsp;Karel W.E. Hulsewé ,&nbsp;Yvonne L.J. Vissers ,&nbsp;Diego Gonzalez-Rivas ,&nbsp;Erik R. de Loos","doi":"10.1016/j.lungcan.2025.108481","DOIUrl":"10.1016/j.lungcan.2025.108481","url":null,"abstract":"<div><h3>Background and objectives</h3><div>Uniportal video-assisted thoracoscopic surgery (VATS) is an accepted surgical technique for lung cancer surgery worldwide. However, data on national patterns of uniportal VATS lung cancer resections are lacking. This study assessed the implementation and clinical practice of uniportal VATS in the Netherlands compared to other surgical approaches.</div></div><div><h3>Methods</h3><div>Data on anatomical lung resections performed for suspected lung cancer from January 2017 to December 2021 were collected from the Dutch Lung Cancer Audit for Surgery registry. Eligible procedures included those performed by uniportal VATS, multiportal VATS, robotic-assisted thoracoscopic surgery, or open surgery, excluding discontinued procedures or those performed in hospital registration years less than 20 resections.</div></div><div><h3>Results</h3><div>The use of uniportal VATS increased from 13 % in 2017 to 21 % in 2021, with the number of hospitals using this technique rising from 30 % to 41 %, reaching a plateau in the last two years. In 2021, 429 resections using uniportal VATS were performed, demonstrating a superior median hospitalization of 4 days and a non-inferior complication rate of 27 % compared to other minimally invasive approaches.</div></div><div><h3>Conclusions</h3><div>Uniportal VATS in the Netherlands reached a plateau in 2020 and 2021. This technique is particularly performed for the removal of early-stage tumors and has similar surgical outcomes as the other thoracoscopic approaches.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"202 ","pages":"Article 108481"},"PeriodicalIF":4.5,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143611748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying and exploring patient engagement interventions for people diagnosed with lung cancer: A rapid systematic review","authors":"S. Cooke ,&nbsp;D. Nelson ,&nbsp;A. Arslan Argin ,&nbsp;D. Laparidou ,&nbsp;R. Young ,&nbsp;J. Waller ,&nbsp;R. Kane ,&nbsp;D. McInnerney ,&nbsp;S.L. Quaife ,&nbsp;M.D. Peake ,&nbsp;L. Mitchinson","doi":"10.1016/j.lungcan.2025.108484","DOIUrl":"10.1016/j.lungcan.2025.108484","url":null,"abstract":"<div><h3>Purpose</h3><div>To identify and synthesise evidence describing patient engagement interventions that have been used to support people diagnosed with lung cancer.</div></div><div><h3>Methods</h3><div>A rapid systematic review was conducted following guidance from the Cochrane Rapid Reviews Methods group and reported using the Preferred Reporting Item for Systematic Review and Meta-analysis (PRISMA) checklist. Keyword searches were performed in MEDLINE and supplemented by Google Scholar searches. Searches were restricted to peer-reviewed articles conducted in high-income countries and published in English. Data was extracted using the Template for Intervention Description and Replication (TIDieR) checklist, tabulated, and narratively synthesised. Data extraction and quality assessment were conducted by two independent reviewers.</div></div><div><h3>Results</h3><div>Thirty-four studies were included in the final analysis. Studies show a positive impact of interventions across a range of engagement outcomes including patient and caregiver knowledge, patient activation, and decision making. Interventions were also shown to reduce healthcare use, reduce symptom severity, and improve psychosocial outcomes. Barriers to implementing interventions included: the timing/delivery of interventions, poor digital literacy, system and technical barriers, and poor uptake and adherence by advanced patients. Factors supporting intervention implementation included: participatory research/co-production approaches, providing training and support for those delivering interventions, involving caregivers, and employing broad recruitment strategies. The overall risk of bias for studies ranged from moderate to high.</div></div><div><h3>Conclusion</h3><div>The identified interventions demonstrate significant potential for enhancing patient engagement and improving outcomes for lung cancer patients. Findings from this review will support the design and implementation of future interventions to help people with cancer engage with healthcare.</div><div><strong>Review registration:</strong> The protocol was registered on the International Prospective Register of Systematic Reviews (PROSPERO) (CRD42024521052) on 06/03/24.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"202 ","pages":"Article 108484"},"PeriodicalIF":4.5,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143628818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}